Tech Company Financing Transactions
Inotrem Funding Round
Inotrem closed a funding round on 1/9/2023. Backers included Crohn's & Colitis Foundation.
Transaction Overview
Company Name
Announced On
1/9/2023
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Crohn's & Colitis Foundation (Lead Investor)
Proceeds Purpose
This funding will help us to expand our patented technology platform centered around the TREM-1 pathway and dedicated to developing new therapies for chronic inflammatory syndromes next to our existing modalities for acute diseases," indicates Sven Zimmermann, CEO of Inotrem.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
54 rue de Ponthieu
Paris, 75008
FR
Paris, 75008
FR
Phone
Website
Email Address
Overview
Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1, to control unbalanced and dysregulated inflammatory responses.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sven Zimmermann
Chief Operating Officer
Martin Koch
Co-Founder
Marc Derive
Co-Founder
Jean Garaud
Browse more venture capital transactions:
Prev: 1/9/2023: Carbon Health venture capital transaction
Next: 1/9/2023: LioniX venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs